Product Summary
VALNEB CR 200 TABLET contains a controlled-release combination of Sodium Valproate and Valproic Acid, belonging to the anticonvulsant/antiepileptic class. Valproate works through several mechanisms that help regulate excessive neuronal activity in the central nervous system. The CR formulation is designed to provide controlled release of the active ingredients over time. It is a prescription medicine and should be used strictly under the supervision of a qualified healthcare professional.
Product Full Description
VALNEB CR 200 TABLET contains Sodium Valproate and Valproic Acid in a controlled-release formulation.
These active ingredients are closely related forms of valproate and exert anticonvulsant effects through multiple neurological pathways.
Valproate increases inhibitory GABA-mediated activity and influences voltage-dependent ion channels involved in neuronal excitability.
The controlled-release formulation is designed to provide a more sustained release of the medicine compared with immediate-release formulations.
The 200 mg strength provides a defined dose that can be incorporated into an individualized treatment regimen.
Because valproate therapy requires careful dose selection and monitoring, VALNEB CR 200 should only be taken according to medical advice.
Usage Instructions
Take VALNEB CR 200 TABLET exactly as prescribed by your doctor.
Swallow the controlled-release tablet whole with water.
Do not crush, chew, or break the tablet unless the product-specific instructions explicitly permit this.
Take it at the same time each day to maintain a consistent dosing schedule.
Follow your doctor's instructions regarding whether it should be taken with or without food.
Do not independently increase, decrease, or change the frequency of doses.
Do not discontinue long-term valproate treatment abruptly without medical guidance.
If you miss a dose, follow your doctor's or pharmacist's instructions rather than taking an extra dose without advice.
Medicinal Advantages
Anticonvulsant activity: Valproate helps regulate excessive neuronal excitability through multiple mechanisms.
Multiple neurological mechanisms: It influences GABA-mediated inhibitory signaling and several voltage-dependent ion channels.
Controlled-release formulation: The CR formulation is designed to provide sustained medicine release over an extended period.
Defined 200 mg strength: Provides a specific strength for individualized dosing under medical supervision.
Established valproate therapy: Valproate medicines have well-established clinical use in selected neurological and psychiatric treatment settings when prescribed appropriately.
Mechanism of Action
Valproate has a multimodal mechanism of action. It can increase the availability and activity of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter that helps reduce excessive neuronal firing.
Valproate also influences voltage-dependent sodium and calcium channels, helping stabilize neuronal membranes and reduce abnormal electrical activity. Its combined effects on inhibitory neurotransmission and neuronal ion channels contribute to its anticonvulsant properties.
The controlled-release formulation modifies the rate at which the medicine is released, supporting a more sustained exposure compared with conventional immediate-release preparations.
Off-Label Uses
Valproate or valproate-containing medicines may occasionally be prescribed outside officially approved indications in selected clinical circumstances based on a healthcare professional's judgment. Such use is considered off-label and should not be interpreted as an officially approved indication.
Any off-label use should be determined by a qualified physician after considering the patient's medical history, treatment objectives, current evidence, and applicable guidelines. Patients should not use VALNEB CR 200 for an unapproved condition without medical supervision.
Expert Advice
VALNEB CR 200 is a prescription medicine and should be used only under qualified medical supervision.
Take the medicine consistently and follow the prescribed dosing schedule.
Because this is a controlled-release formulation, do not crush or chew the tablet unless specifically permitted by the product information.
Valproate therapy may require clinical and laboratory monitoring as determined by the treating physician.
Inform your healthcare professional about existing liver, pancreatic, metabolic, or neurological conditions.
Discuss all current medicines and supplements with your doctor before starting or changing treatment.
Women who are pregnant, planning pregnancy, or capable of becoming pregnant should discuss valproate treatment with their healthcare professional because of important pregnancy-related safety considerations.
Do not stop ongoing therapy suddenly without medical guidance.
Precautions
Liver function: Valproate can require particular caution in patients with existing liver disease. Your doctor may assess liver function when clinically appropriate.
Pregnancy: Valproate carries significant pregnancy-related risks and should be discussed carefully with a qualified healthcare professional before use during pregnancy or when planning pregnancy.
Pancreatic conditions: Inform your doctor about any history of pancreatic disease before treatment.
Blood and metabolic monitoring: Your healthcare professional may recommend appropriate laboratory monitoring during treatment, particularly during prolonged therapy.
Kidney function: Patients with impaired kidney function may require individualized medical assessment and monitoring.
Dose changes: Do not independently increase, reduce, or discontinue the prescribed dose.
Controlled-release formulation: Swallow the tablet according to the manufacturer's instructions and do not alter the dosage form without professional advice.
Storage Conditions
Store VALNEB CR 200 according to the manufacturer's recommended conditions.
Keep the tablets in their original packaging.
Protect from excessive heat, moisture, and direct sunlight.
Keep out of reach of children and pets.
Do not use the medicine after the expiry date printed on the packaging.
FAQs
What is VALNEB CR 200 TABLET?
VALNEB CR 200 is a controlled-release valproate formulation containing Sodium Valproate and Valproic Acid. It belongs to the anticonvulsant/antiepileptic class.
What does CR mean in VALNEB CR 200?
CR means controlled release. The formulation is designed to release the active ingredients in a controlled manner rather than all at once.
How does VALNEB CR 200 work?
Valproate works through multiple neurological mechanisms, including enhancement of inhibitory GABA activity and modulation of voltage-dependent ion channels involved in neuronal excitability.
Can VALNEB CR 200 be crushed or chewed?
Controlled-release tablets generally should not be crushed or chewed because altering the dosage form can affect how the medicine is released. Follow the specific instructions supplied with your product.
Is VALNEB CR 200 a prescription medicine?
Yes. Valproate treatment requires appropriate medical supervision and individualized dosing.
Does VALNEB CR 200 require monitoring?
Depending on the patient's circumstances and treatment duration, a healthcare professional may recommend clinical assessments and laboratory monitoring during valproate therapy.
Can VALNEB CR 200 be stopped suddenly?
Do not stop long-term valproate treatment without consulting your doctor. Your healthcare professional can determine the appropriate approach to changing or discontinuing therapy.
How should VALNEB CR 200 be stored?
Keep it in its original packaging under the manufacturer's recommended storage conditions, away from excessive heat, moisture, and direct sunlight.
Suggested Product Tags
VALNEB CR 200, VALNEB CR 200 TABLET, VALNEB CR TABLET, SODIUM VALPROATE 200 MG, VALPROIC ACID TABLET, SODIUM VALPROATE AND VALPROIC ACID, SODIUM VALPROATE VALPROIC ACID CR, VALPROATE CR TABLET, VALPROATE CONTROLLED RELEASE TABLET, VALPROATE MEDICINE, ANTICONVULSANT MEDICINE, ANTIEPILEPTIC MEDICINE, VALPROATE 200 MG TABLET, PRESCRIPTION ANTICONVULSANT, VALNEB TABLET
